Novartis to In-Licence ECF843 to Strengthen R&D pipeline
Novartis announced that it has it has it has exercised an option to in-license ECF843 for ophthalmic indication worldwide to strengthen R&D pipeline. The closing of the deal is…
Read More...
Read More...
